Needham & Company LLC reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report published on Friday morning,Benzinga reports. They ...
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan ...
Researchers developed a new gene-editing strategy that dramatically boosts the effectiveness of gene therapies in the liver, a breakthrough that could lead to new treatments for about 700 genetic ...
Oligonucleotide therapies are among the most promising biological therapeutics. They target disease at a different stage of ...
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...
Scotiabank lowered the firm’s price target on Alnylam (ALNY) to $300 from $310 and keeps an Outperform rating on the shares. The firm is ...
Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $329.00. The ...
The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...
Bristol Myers Squibb Co. devoted half a page of its annual report to its diversity, equity and inclusion efforts, going so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback